Brief introduction of Chifeng Aike Pharmaceutical Technology Co., Ltd.

The business scope of the company mainly includes the production and sales of ephedrine and other raw materials, small water injections, tablets, capsules, granules and powders; Development, introduction, transfer, consultation, service and training of new pharmaceutical products and technologies. The main products are ephedrine hydrochloride, pseudoephedrine hydrochloride, racemic methylephedrine hydrochloride, methylephedrine hydrochloride, pseudoephedrine sulfate, norpseudoephedrine hydrochloride and its series products, as well as chemical synthetic products such as dirithromycin, ipriflavone and balsalazide.

Chemical extraction of ephedra to produce ephedrine has inherited the production technology of Chifeng Pharmaceutical Factory for more than 50 years, and has a perfect, advanced and stable technological process. Its chemical extraction products go down in history as the first pharmaceutical and chemical raw materials in China, and ephedrine hydrochloride and pseudoephedrine hydrochloride both won the national quality gold medal. 200 1 put into production, the ephedrine production project by chemical synthesis conforms to the national industrial policy and has independent intellectual property rights. It is a pioneer in the chemical synthesis of ephedrine in the world and has the international leading level. With the implementation of this project, our company has become the only enterprise in China that produces ephedrine on a large scale by full chemical method. With the continuous enhancement of people's awareness of environmental protection and the gradual expansion of the scale of ephedrine production by full chemical method, ephedrine production by full chemical synthesis method will gradually replace chemical extraction of ephedra to produce ephedrine, and its ecological and economic benefits will also be fully demonstrated. Ephedrine produced by chemical method participates in domestic and international market competition with its advanced technology, high-quality products and competitive cost, which promotes the development of ephedrine industry in China. As the first technology in China, the chemical method to produce synthetic ephedrine has been included in the "two high and one excellent" project of the State Economic and Trade Commission, the torch project of the Ministry of Science and Technology and the seventh national debt discount project.

For the development of the enterprise, the company has done a lot of work in product export. In 2002, the company took the lead in passing the on-site inspection of the US Food and Drug Administration (FDA) in the same industry, and passed the European Pharmacopoeia Applicability Certification (COS Certificate) at the end of the same year. Our company is the only company in China that has passed FDA inspection and COS certification. This has opened up a green channel to enter the international European and American markets, and gradually established long-term cooperative relations with many internationally renowned companies, and the export volume of products has increased year by year. The company has improved the quality assurance system, and passed the quality audits of GlaxoSmithKline, Sino-American SmithKline, Wyeth Baigong Pharmaceutical Company, American Bellicott Company, Shanghai Squibb Company and Shanghai Johnson & Johnson Pharmaceutical Company successively, and won the best supplier of Sino-American SmithKline Tianjin Pharmaceutical Co., Ltd. for three consecutive years. In 2005, it was awarded the title of best partner and excellent supplier of Shanghai Johnson & Johnson Pharmaceutical Company, and in 2007, it was awarded the title of excellent supplier of Shanghai Johnson & Johnson Pharmaceutical Company. Through the annual supplier audit of the above-mentioned companies, our company has been improved in product quality and service, operation process, rules and regulations, etc., and won a high commercial reputation in the same industry at home and abroad, laying a solid foundation for the company's subsequent development.